false
English
Catalog
2025 Hot Topic in Basic & Translational Science: S ...
EP01.05: Evaluating therapeutic marker expression ...
EP01.05: Evaluating therapeutic marker expression and EMT heterogeneity in circulating tumor cells from SCLC liquid biopsies using mass cytometry
Back to course
Pdf Summary
This study investigates the utility of mass cytometry (CyTOF) for analyzing circulating tumor cells (CTCs) in liquid biopsies from patients with Small Cell Lung Cancer (SCLC). Traditional tissue biopsies can be challenging due to tumor inaccessibility and patient health, so liquid biopsies offer a non-invasive alternative to study tumor dynamics in real-time. Despite the potential of CTCs for biomarker analyses in SCLC, they are seldom examined at single-cell resolution, a gap this study aims to address.<br /><br />Using CyTOF, the researchers performed deep phenotyping of CTCs directly from SCLC patient liquid biopsies. They identified CTCs based on negative CD45 and positive CD56 expression, further confirmed by TTF1 positivity. The study optimized a 20-marker antibody panel for CyTOF analysis, which revealed higher expression of SCLC subtype-specific transcription factors, CD24, and DLL3 in patient CTCs compared to healthy donors.<br /><br />The study successfully identified the four established SCLC subtypes within the CTCs, showcasing high heterogeneity in epithelial-mesenchymal transition (EMT) states, which requires further study. Significantly, the analysis observed a shift towards a more mesenchymal phenotype in CTCs from treatment-naïve to the treated/relapsed patient group, which may signal adaptive resistance mechanisms.<br /><br />The longitudinal tracking of patients, especially those undergoing tarlatamab treatment, indicated significant upregulation of CD24, potentially implicating it in resistance to anti-DLL3 therapy. This research marks the first use of CyTOF for single-cell proteomic profiling of CTCs in SCLC, highlighting its potential for real-time monitoring of disease progression and therapy response. It suggests that CyTOF could advance personalized medicine by enabling detailed phenotypic mapping of EMT and drug resistance states, offering insights into therapy response and resistance mechanisms.
Asset Subtitle
Mukulika Bose
Keywords
mass cytometry
CyTOF
circulating tumor cells
liquid biopsies
Small Cell Lung Cancer
SCLC
biomarker analyses
epithelial-mesenchymal transition
tarlatamab treatment
personalized medicine
×
Please select your language
1
English
5
普通话
11
Dutch